Xenon Pharmaceuticals will announce Phase 3 trial data for azetukalner in focal onset seizures on March 9, 2026.
Quiver AI Summary
Xenon Pharmaceuticals Inc., a biopharmaceutical company focused on neuroscience, announced that it will release topline data from the Phase 3 X-TOLE2 study of its drug azetukalner, a KV7 potassium channel opener, for treating focal onset seizures, on March 9, 2026. The company will host a conference call and webcast on the same day at 8:00 am ET. Azetukalner is currently in Phase 3 trials for epilepsy as well as for major depressive disorder and bipolar depression, while Xenon is also developing other potassium and sodium channel modulators for pain management. For further details, investors and media can contact the provided representatives.
Potential Positives
- Xenon Pharmaceuticals will announce topline data from the Phase 3 X-TOLE2 study of azetukalner, indicating progress in clinical development for a novel epilepsy treatment.
- The company's lead molecule, azetukalner, represents a significant potential advancement in treating focal onset seizures, major depressive disorder, and bipolar depression.
- Xenon's commitment to advancing a diverse portfolio of early-stage potassium and sodium channel modulators highlights its innovative approach in the neuroscience field.
Potential Negatives
- The press release announces a forthcoming data release for the Phase 3 X-TOLE2 study, indicating that the company has not yet provided conclusive results about the efficacy or safety of azetukalner in treating focal onset seizures.
- The lack of detailed data or results in the press release may lead to uncertainty among investors regarding the future success of the drug and the company's prospects.
- The mention of multiple ongoing clinical trials without highlighting any successes or advancements may suggest challenges in the commercialization of their product portfolio.
FAQ
What is the date of the topline data announcement for azetukalner?
The topline data from the Phase 3 X-TOLE2 study of azetukalner will be announced on March 9, 2026.
What is azetukalner?
Azetukalner is a novel, potent KV7 potassium channel opener currently in Phase 3 trials for treating focal onset seizures.
How can I access the conference call for the announcement?
You can join the conference call by dialing (800) 715-9871 or by pre-registering for the webcast.
Where is Xenon Pharmaceuticals located?
Xenon Pharmaceuticals has offices in Vancouver, British Columbia, and Boston, Massachusetts.
What therapeutic areas does Xenon focus on?
Xenon focuses on drug development for epilepsy, major depressive disorder, and bipolar depression, among other areas.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$XENE Insider Trading Activity
$XENE insiders have traded $XENE stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $XENE stock by insiders over the last 6 months:
- IAN MORTIMER (PRESIDENT & CEO) has made 0 purchases and 7 sales selling 90,302 shares for an estimated $3,927,972.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$XENE Hedge Fund Activity
We have seen 127 institutional investors add shares of $XENE stock to their portfolio, and 113 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BRAIDWELL LP removed 1,779,953 shares (-49.4%) from their portfolio in Q4 2025, for an estimated $79,777,493
- WELLINGTON MANAGEMENT GROUP LLP added 1,154,922 shares (+32.0%) to their portfolio in Q4 2025, for an estimated $51,763,604
- COMMODORE CAPITAL LP removed 900,000 shares (-33.3%) from their portfolio in Q4 2025, for an estimated $40,338,000
- DEEP TRACK CAPITAL, LP removed 833,565 shares (-69.5%) from their portfolio in Q4 2025, for an estimated $37,360,383
- PRICE T ROWE ASSOCIATES INC /MD/ added 820,608 shares (+1968.3%) to their portfolio in Q4 2025, for an estimated $36,779,650
- MILLENNIUM MANAGEMENT LLC removed 748,951 shares (-54.1%) from their portfolio in Q4 2025, for an estimated $33,567,983
- HOLOCENE ADVISORS, LP removed 694,472 shares (-35.1%) from their portfolio in Q4 2025, for an estimated $31,126,235
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$XENE Analyst Ratings
Wall Street analysts have issued reports on $XENE in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 11/18/2025
- Needham issued a "Buy" rating on 11/04/2025
- RBC Capital issued a "Outperform" rating on 11/04/2025
- Chardan Capital issued a "Buy" rating on 10/07/2025
To track analyst ratings and price targets for $XENE, check out Quiver Quantitative's $XENE forecast page.
$XENE Price Targets
Multiple analysts have issued price targets for $XENE recently. We have seen 6 analysts offer price targets for $XENE in the last 6 months, with a median target of $58.0.
Here are some recent targets:
- Serge Belanger from Needham set a target price of $58.0 on 02/27/2026
- Benjamin Burnett from Wells Fargo set a target price of $49.0 on 02/27/2026
- Rudy Li from Wolfe Research set a target price of $60.0 on 02/24/2026
- Tessa Romero from JP Morgan set a target price of $62.0 on 01/09/2026
- Brian Abrahams from RBC Capital set a target price of $58.0 on 11/04/2025
- Rudy Li from Chardan Capital set a target price of $55.0 on 10/07/2025
Full Release
VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, will announce topline data from the Phase 3 X-TOLE2 study of azetukalner, a novel, potent K V 7 potassium channel opener, in patients with focal onset seizures (FOS), on Monday, March 9, 2026.
| Conference Call/Webcast Information: | |
| Date: | Monday, March 9, 2026 |
| Time: | 8:00 am ET (5:00 am PT) |
| Webcast: | Pre-register here |
| Dial-In: |
(800) 715-9871 toll-free or (646) 307-1963 for international callers
|
| Conference ID: | 7885306 |
A live webcast of the company presentation will be available on the Investors section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent K V 7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including K V 7 and Na V 1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X .
Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.
Contacts
For Investors:
Tucker Kelly
Chief Financial Officer
[email protected]
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
[email protected]
